Skip to main content
. 2019 May 17;37(19):1608–1616. doi: 10.1200/JCO.19.00538

FIG A4.

FIG A4.

Progression-free survival (PFS) by tumor programmed death ligand 1 (PD-L1) expression per investigator. (A) NIVO3 (nivolumab 3 mg/kg monotherapy every 2 weeks). (B) NIVO3+IPI1 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks). (C) NIVO1+IPI3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks).